Immune Pharmaceuticals Stock Total Debt
Immune Pharmaceuticals fundamentals help investors to digest information that contributes to Immune Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Immune OTC Stock. The fundamental analysis module provides a way to measure Immune Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immune Pharmaceuticals otc stock.
Immune |
Immune Pharmaceuticals OTC Stock Total Debt Analysis
Immune Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Immune Pharmaceuticals Total Debt | 8.33 M |
Most of Immune Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immune Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Immune Pharmaceuticals has a Total Debt of 8.33 M. This is 99.7% lower than that of the Healthcare sector and 99.95% lower than that of the Drug Manufacturers - Major industry. The total debt for all United States stocks is 99.84% higher than that of the company.
Immune Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immune Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Immune Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Immune Pharmaceuticals by comparing valuation metrics of similar companies.Immune Pharmaceuticals is currently under evaluation in total debt category among related companies.
Immune Fundamentals
| Return On Asset | -42.63 | |||
| Current Valuation | 8.67 M | |||
| Shares Outstanding | 72.38 M | |||
| Shares Owned By Insiders | 2.16 % | |||
| Shares Owned By Institutions | 0.06 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | (0.17) X | |||
| Price To Book | 0.40 X | |||
| Price To Sales | 858.11 X | |||
| Revenue | 19 K | |||
| EBITDA | (13.77 M) | |||
| Net Income | (34.39 M) | |||
| Cash And Equivalents | 76 K | |||
| Total Debt | 8.33 M | |||
| Debt To Equity | 989.50 % | |||
| Current Ratio | 0.02 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (14.69 M) | |||
| Short Ratio | 1.32 X | |||
| Earnings Per Share | (1.15) X | |||
| Beta | 2.99 | |||
| Market Capitalization | 553.21 K | |||
| Total Asset | 36.18 M | |||
| Retained Earnings | (62.99 M) | |||
| Working Capital | (1.45 M) | |||
| Current Asset | 4.83 M | |||
| Current Liabilities | 6.29 M | |||
| Z Score | -1.4 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immune Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immune Pharmaceuticals' short interest history, or implied volatility extrapolated from Immune Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Immune OTC Stock
If you are still planning to invest in Immune Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Pharmaceuticals' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stocks Directory Find actively traded stocks across global markets |